DailyIQ
|
Sector:HealthcareAll sectors
Last updated 23 minutes ago

EW·Edwards Lifesciences Corporation

$.
+. (+.%)
High
$90.99
Open
$87.35
Market Cap
49.82B
52W High
$89.60
Low
$87.00
P. Close
$86.95
P/E
45.45
52W Low
$72.30
Fwd P/E
25.82
DailyIQ Est.
$99.24
Technical Score (1D)
82
BUY
News Sentiment
-
NO DATA
The CMS expansion of Medicare reimbursement for transcatheter aortic valve replacement (TAVR) is poised to lift demand for Edwards Lifesciences’ (EW) transcatheter valves, a development highlighted by RBC analysts. The rule’s broader coverage is expected to increase procedure volumes, which could translate into a revenue boost for EW and strengthen its competitive edge over rivals Medtronic and Boston Scientific. This potential uptick in utilization will be reflected in EW’s quarterly TAVR volume reports, providing early evidence of the rule’s impact. RBC maintains an Outperform rating and a $100 price target, underscoring confidence in the company’s market position amid the regulatory change. Analysts note that EW’s recent earnings already show robust growth from TAVR procedures, but macro headwinds and currency volatility could temper upside in the near term. The timing of the rule’s final implementation date will be a key event for investors to watch, as it determines when the increased reimbursement will take effect. Traders should also monitor EW’s upcoming earnings guidance for any updates on TAVR revenue growth. Additionally, any adjustments to reimbursement rates by CMS could further influence procedure volumes and revenue projections. Finally, keeping an eye on macro data releases and currency movements will help gauge the broader economic backdrop that could affect EW’s performance over the next 1–10 trading days.
Earnings Summary
Edwards Lifesciences (EW) is a global medical‑technology company that designs and markets transcatheter heart‑valve solutions, including the SAPIEN, PASCAL PRECISION, and Cardioband platforms, and surgical valves such as INSPIRIS and MITRIS RESILIA, serving patients in the United States, Europe, Japan and beyond. In the highly competitive cardiovascular‑devices sector, the firm’s focus on minimally invasive aortic, mitral and tricuspid valve therapies positions it as a leader in a market driven by aging populations and expanding procedural indications. In the most recent two quarters, EW reported revenue of $1.5696 billion in Q4 2025 and $1.6486 billion in Q1 2026, up 13.8 % and 16.8 % YoY respectively, while EPS rose from $0.58 to $0.78, a 21 % increase; the company beat revenue estimates in both periods and earned a $0.78 EPS versus a $0.749 estimate in Q1 2026, but missed the $0.69034 EPS estimate in Q4 2025. Compared with the prior two quarters (Q3 2025 $1.5531 billion, $0.67 EPS; Q2 2025 $1.5322 billion, $0.67 EPS), revenue has accelerated and EPS has improved, with the firm achieving a 2‑out‑of‑3 quarter earnings‑beat streak. Historically, EW has posted double‑digit revenue growth year over year, with the latest quarter showing a 13.8 % YoY increase, while EPS has fluctuated, reflecting the impact of one‑off charges and currency swings; nevertheless, the company has consistently outperformed revenue estimates across the last four quarters. Recent news highlights a CMS proposal to expand Medicare reimbursement for transcatheter aortic valve replacement, a change that could lift TAVR volumes and strengthen EW’s competitive position; analysts note that the rule’s implementation date will be a key event, and that macro headwinds and currency volatility could temper the upside. Investors should watch for the CMS decision announcement, quarterly TAVR volume reports, currency movements in the euro and yen, and any guidance updates from the newly appointed CFO, as these factors will shape the next earnings cycle.

EPS

EstBeatMiss
$0.55$0.61$0.68$0.74$0.81Q1'25Q2'25Q3'25Q4'25Q1'26Q2'26
QtrEstActual+/−
Q2'26$0.74 - -
Q1'26$0.75$0.78+4.1%
Q4'25$0.69$0.58-16.0%
Q3'25$0.59$0.67+12.6%
Q2'25$0.62$0.67+7.6%
Q1'25$0.60$0.64+7.5%

Revenue

EstBeatMiss
$1.4B$1.5B$1.6B$1.7B$1.8BQ1'25Q2'25Q3'25Q4'25Q1'26Q2'26
QtrEstActual+/−
Q2'26$1.8B - -
Q1'26$1.6B$1.6B+0.3%
Q4'25$1.6B$1.6B+0.2%
Q3'25 - $1.6B -
Q2'25 - $1.5B -
Q1'25 - $1.4B -
Full Earnings BreakdownEstimates, actuals, guidance, and historical context
→

Market Data

EW Stock Snapshot

EW is currently trading at $89.33, giving Edwards Lifesciences Corporation a market cap of 49.82B and a P/E ratio of 45.5. Today's range spans $87.00–$90.99, with shares opening at $87.35 and moving up $2.38 (2.7%) from the prior close. DailyIQ's technical score sits at 82/100 (BUY).

Over the past year EW has traded between $72.30 and $89.60 - the current price is +23.6% off the 52-week low and -0.3% from the high. 44 analysts cover the stock with a Buy consensus and a mean 12-month target of $96.92 (range $84.00–$110.00), implying upside of +8.5%.

Cross-asset context supports the bullish read on EW: when Healthcare sector conditions are favorable, large-cap names with 82/100 technical scores (BUY) and neutral sentiment (-/100) outperform on a risk-adjusted basis. Price: $89.33 (near 52-week highs). (P/E: 45.5) The 52-week context of $72.30–$89.60 shows the full trading history - and the current setup is one of the stronger entries within that range. At 49.82B in market cap, position sizing is the key variable, not the direction.

The combination of a BUY signal (82/100) and neutral news sentiment (-/100) puts EW on the screens of active managers who run quality-momentum overlays — a cohort that can build meaningful positions at 49.82B in Healthcare market cap without immediately moving the stock. At $89.33 (near 52-week highs in the $72.30–$89.60 range), the entry discipline is clean and the potential re-rating if sentiment continues to improve is meaningful.